In-vitro Diagnostics Enzymes Market (By Enzyme Type: Proteases, Polymerase & Transcriptase, Ribonuclease, Others; By Disease Type: Infectious Disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, Others; By Technology Type: Histology Assays, Molecular Diagnostics, Clinical Chemistry; By End-use: Pharma & Biotech, Hospital & Diagnostic Labs, Contract Research Organizations, Academic Labs) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on In-vitro Diagnostics Enzymes Market
5.1. COVID-19 Landscape: In-vitro Diagnostics Enzymes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global In-vitro Diagnostics Enzymes Market, By Enzyme Type
8.1. In-vitro Diagnostics Enzymes Market, by Enzyme Type, 2024-2033
8.1.1. Proteases
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Polymerase & Transcriptase
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Ribonuclease
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global In-vitro Diagnostics Enzymes Market, By Disease Type
9.1. In-vitro Diagnostics Enzymes Market, by Disease Type, 2024-2033
9.1.1. Infectious Disease
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Diabetes
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Cardiology
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Nephrology
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Autoimmune diseases
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global In-vitro Diagnostics Enzymes Market, By Technology Type
10.1. In-vitro Diagnostics Enzymes Market, by Technology Type, 2024-2033
10.1.1. Histology Assays
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Molecular Diagnostics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Clinical Chemistry
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global In-vitro Diagnostics Enzymes Market, By End-use
11.1. In-vitro Diagnostics Enzymes Market, by End-use, 2024-2033
11.1.1. Pharma & Biotech
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Hospital & Diagnostic Labs
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Contract Research Organizations (CROs)
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Academic Labs
11.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global In-vitro Diagnostics Enzymes Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.1.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.1.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.4. Market Revenue and Forecast, by End-use (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.2.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.2.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.3.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.3.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.4.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 13. Company Profiles
13.1. Biocatalysts Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amicogen
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dyadic International
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. BBI Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Affymetrix
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. American Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Codexis, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Amano Enzyme Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample